CADL - CIK 0001841387
Candel Therapeutics, Inc. (CADL) reported net income of -$38.18M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$38.18M | +30.8% |
| FY 2024 | -$55.18M | -45.4% |
| FY 2023 | -$37.94M | -101.9% |
| FY 2022 | -$18.79M | +48.0% |
| FY 2021 | -$36.12M | -104.3% |
| FY 2020 | -$17.68M | - |
Candel Therapeutics, Inc. (CADL) reported net income of -$38.18M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Candel Therapeutics, Inc.'s net income declined from -$17.68M to -$38.18M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.